CA3145579A1 - Process for manufacturing (s)-3-hydroxy-1-(1h-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide - Google Patents
Process for manufacturing (s)-3-hydroxy-1-(1h-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide Download PDFInfo
- Publication number
- CA3145579A1 CA3145579A1 CA3145579A CA3145579A CA3145579A1 CA 3145579 A1 CA3145579 A1 CA 3145579A1 CA 3145579 A CA3145579 A CA 3145579A CA 3145579 A CA3145579 A CA 3145579A CA 3145579 A1 CA3145579 A1 CA 3145579A1
- Authority
- CA
- Canada
- Prior art keywords
- indo1
- hydroxy
- oxo
- pyrrolidine
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- WVGGJQVCOTYFPV-FQEVSTJZSA-N (3s)-n-[(3,5-difluorophenyl)methyl]-3-hydroxy-1-(1h-indol-5-yl)-2-oxopyrrolidine-3-carboxamide Chemical compound O=C([C@@]1(C(N(CC1)C=1C=C2C=CNC2=CC=1)=O)O)NCC1=CC(F)=CC(F)=C1 WVGGJQVCOTYFPV-FQEVSTJZSA-N 0.000 title abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 28
- VJNGGOMRUHYAMC-UHFFFAOYSA-N (3,5-difluorophenyl)methanamine Chemical compound NCC1=CC(F)=CC(F)=C1 VJNGGOMRUHYAMC-UHFFFAOYSA-N 0.000 claims description 14
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 claims description 13
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 6
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 claims description 6
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 claims description 6
- JGQPSDIWMGNAPE-UHFFFAOYSA-N 2,1-benzothiazole Chemical compound C1=CC=CC2=CSN=C21 JGQPSDIWMGNAPE-UHFFFAOYSA-N 0.000 claims description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 229960004132 diethyl ether Drugs 0.000 claims description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 40
- 229940093499 ethyl acetate Drugs 0.000 description 30
- 235000019439 ethyl acetate Nutrition 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 239000007787 solid Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- -1 Et0H Chemical compound 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 5
- MKHGVMIXRPGHOO-UHFFFAOYSA-N 2-(benzenesulfonyl)-3-phenyloxaziridine Chemical compound C=1C=CC=CC=1S(=O)(=O)N1OC1C1=CC=CC=C1 MKHGVMIXRPGHOO-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 238000004296 chiral HPLC Methods 0.000 description 4
- 229940052303 ethers for general anesthesia Drugs 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000004808 supercritical fluid chromatography Methods 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- FODOUIXGKGNSMR-UHFFFAOYSA-L magnesium;2-oxidooxycarbonylbenzoate;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[O-]OC(=O)C1=CC=CC=C1C([O-])=O FODOUIXGKGNSMR-UHFFFAOYSA-L 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 2
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- GPDHNZNLPKYHCN-DZOOLQPHSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCOC(=O)C(\C#N)=N/OC(=[N+](C)C)N1CCOCC1 GPDHNZNLPKYHCN-DZOOLQPHSA-N 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 150000004693 imidazolium salts Chemical class 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 102100032859 Protein AMBP Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- LCKIEQZJEYYRIY-UHFFFAOYSA-N Titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 description 1
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 1
- FYJKEHKQUPSJDH-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;potassium Chemical compound [K].C[Si](C)(C)N[Si](C)(C)C FYJKEHKQUPSJDH-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- ZOAIGCHJWKDIPJ-UHFFFAOYSA-M caesium acetate Chemical compound [Cs+].CC([O-])=O ZOAIGCHJWKDIPJ-UHFFFAOYSA-M 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000950 dibromo group Chemical group Br* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- LWJUQIOWBKYOMO-UHFFFAOYSA-N n,n-dimethylpyren-1-amine Chemical compound C1=C2C(N(C)C)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 LWJUQIOWBKYOMO-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- LMHHRCOWPQNFTF-UHFFFAOYSA-N s-propan-2-yl azepane-1-carbothioate Chemical compound CC(C)SC(=O)N1CCCCCC1 LMHHRCOWPQNFTF-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
Abstract
A process for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo- pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide.
Description
Process for manufacturing (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.
The present invention relates to a process for manufacturing the MetAP-2 inhibitor (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide ("S-9") being synthesized in a key step with an asymmetric oxidizing agent: Davis oxaziridine'.
Davis oxaziridine: (+)-(2R,4aS,7S,8aR)-4H-4a, 7-Methanooxazirino[3, 2-i]
[2, 1] benzisothiazole, 8,8-dichlorotetrahydro-9,9-dimethy1-3,3-dioxide ci Citfl Nflk S
0 o s9j This process for the preparation of "S-9" is not known.
Prior art references WO 2012048775, WO 2013149704 and WO 2016020031 disclose a racemic synthesis for manufacturing the racemic compound followed by chiral separation.
The analysis/comparison of both ways, the racemic synthesis vs the claimed asymmetric route, clearly demonstrates that the asymmetric oxidation is superior compared to the state of the art.
The asymmetric process requires less steps and is higher yielding.
Scheme 1 gives an overview how the routes differ.
The present invention relates to a process for manufacturing the MetAP-2 inhibitor (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide ("S-9") being synthesized in a key step with an asymmetric oxidizing agent: Davis oxaziridine'.
Davis oxaziridine: (+)-(2R,4aS,7S,8aR)-4H-4a, 7-Methanooxazirino[3, 2-i]
[2, 1] benzisothiazole, 8,8-dichlorotetrahydro-9,9-dimethy1-3,3-dioxide ci Citfl Nflk S
0 o s9j This process for the preparation of "S-9" is not known.
Prior art references WO 2012048775, WO 2013149704 and WO 2016020031 disclose a racemic synthesis for manufacturing the racemic compound followed by chiral separation.
The analysis/comparison of both ways, the racemic synthesis vs the claimed asymmetric route, clearly demonstrates that the asymmetric oxidation is superior compared to the state of the art.
The asymmetric process requires less steps and is higher yielding.
Scheme 1 gives an overview how the routes differ.
- 2 -The common intermediate is compound number 5. Starting from this compound 5 the established route requires five additional synthetic steps and chiral chromatography to get the desired enantiomer S-9 in 15%
overall yield.
Via 3 additional steps (R-9 to 10: alcohol activation; 10 to 11: inversion; 11 to S-9: hydrolysis) the yield can be increased but the amount of work is significantly increased.
This new process gives S-9 in three additional steps from 5 in 27% overall yield.
The key step is the enantioselective oxidation of 1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-2-oxopyrrolidine-3-io carboxamide (12) to give (3S)-1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-3-hydroxy-2-oxopyrrolidine-3-carboxamide (13).
Scheme 1:
overall yield.
Via 3 additional steps (R-9 to 10: alcohol activation; 10 to 11: inversion; 11 to S-9: hydrolysis) the yield can be increased but the amount of work is significantly increased.
This new process gives S-9 in three additional steps from 5 in 27% overall yield.
The key step is the enantioselective oxidation of 1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-2-oxopyrrolidine-3-io carboxamide (12) to give (3S)-1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-3-hydroxy-2-oxopyrrolidine-3-carboxamide (13).
Scheme 1:
- 3 -o OXe ).-0H
* Fe, NH4CI 170,06 ON) 0' 5 .1-0 NaH, THF Et0H, H20 CH3CN, DMF
'S
rt, 4 h 80 C, 2 h 70 C, 16 h * + 0.- ii..- / * I
/ 101 OZ:S'N / OZ.-.S'N
HN ob db N
Step 1 Step 2 Step 3 0,6 MMPP,DMF/ 1 Step 4C
Step 4 F 60 C, 2 h T3N, Et3N
"_0 I 0H 0 H
OH F
* F 5 H
HO( _N
0..= *
N
Oy F F
0,' , T3P, Et3N, CH2Cl2 0 N) O Ac20, DMF 0 N
) ON) F
ON rt, 2 h rt, 12 h
* Fe, NH4CI 170,06 ON) 0' 5 .1-0 NaH, THF Et0H, H20 CH3CN, DMF
'S
rt, 4 h 80 C, 2 h 70 C, 16 h * + 0.- ii..- / * I
/ 101 OZ:S'N / OZ.-.S'N
HN ob db N
Step 1 Step 2 Step 3 0,6 MMPP,DMF/ 1 Step 4C
Step 4 F 60 C, 2 h T3N, Et3N
"_0 I 0H 0 H
OH F
* F 5 H
HO( _N
0..= *
N
Oy F F
0,' , T3P, Et3N, CH2Cl2 0 N) O Ac20, DMF 0 N
) ON) F
ON rt, 2 h rt, 12 h
-4 = -4 * Step 6 N / Step 5 N / N /
/
o, , aN Ozzs' 0:_-.s' 0,-_-.s' '5,0 0 0 0 .
7 6 6 ($ 12 NaOH, Et0H, THF NaHMDS
Step 7 Step 50 C, 2 h Davis-Oxaziridine F
F F 0 H *
N
HOy. \
H * F H 011 F
0 N) F
N
OyN 0 NaOH, HO ___________________ SFC separation HOE Et0H/THF
____________________ ..- A _______ (:). N' 0 N 101 Step 6C
110 * 0-,s'N /
/ / /
HN HN
Step 10 C5613 9 S-9 NaOH Me0H
rt, 2 h 0"S
) `", b Cs0Ac, DMF
0 ( JL. ____________ msci, Et3N
F = N ON) .1 NIC
CH2Cl2, 0 C, 2h F 110 HN 0 1 ) 100 C, 2 h F 110 Fl,õ
HY ) ________________________ _ N `-' N
F
* Step 8 F
/
o, , aN Ozzs' 0:_-.s' 0,-_-.s' '5,0 0 0 0 .
7 6 6 ($ 12 NaOH, Et0H, THF NaHMDS
Step 7 Step 50 C, 2 h Davis-Oxaziridine F
F F 0 H *
N
HOy. \
H * F H 011 F
0 N) F
N
OyN 0 NaOH, HO ___________________ SFC separation HOE Et0H/THF
____________________ ..- A _______ (:). N' 0 N 101 Step 6C
110 * 0-,s'N /
/ / /
HN HN
Step 10 C5613 9 S-9 NaOH Me0H
rt, 2 h 0"S
) `", b Cs0Ac, DMF
0 ( JL. ____________ msci, Et3N
F = N ON) .1 NIC
CH2Cl2, 0 C, 2h F 110 HN 0 1 ) 100 C, 2 h F 110 Fl,õ
HY ) ________________________ _ N `-' N
F
* Step 8 F
5 Step 9 F
/ / /
PRIOR ART
Prior art references WO 2012/048775, WO 2013/149704 and WO 2016020031 disclose a racemic synthesis for manufacturing the racemic compound followed by chiral separation.
(S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide is disclosed as "B8" in WO 2013/149704.
SUMMARY OF THE INVENTION
The invention relates to a process for manufacturing (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide ("S-9"), characterized in that a) 2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-yl)pyrrolidine-3-carboxylic acid ("5") is reacted with 3,5-difluorobenzyl amine to give 1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-2-oxopyrrolidine-3-carboxamide ("12"), b) "12" is then enantioselectively oxidized to give (3S)-1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-3-hydroxy-2-oxopyrrolidine-3-carboxamide ("13"), c) and subsequently the phenylsulfonyl group is cleaved off from "13" to give (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylam ide ("S-9").
Preferably the invention relates to a process for manufacturing (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide ("S-9"), characterized in that 2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-yl)pyrrolidine-3-carboxylic acid ("5") is reacted with 3,5-difluorobenzyl amine to give 1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-2-oxopyrrolidine-3-carboxamide ("12"), "12" is then reacted with (+)-(2R,4aS,7S,8aR)-4H-4a, 7-methanooxazirino[3, 2-i] [2, 1] benzisothiazole, 8,8-dichlorotetrahydro-9,9-dimethy1-3,3-dioxide to give (3S)-1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-3-hydroxy-2-oxopyrrolidine-3-carboxamide ("13"), and subsequently the phenylsulfonyl group is cleaved off from "13" to give (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide ("S-9").
The reaction of compound 5 with 3,5-difluorobenzyl amine in step 4C is generally carried out in the presence of an a organic base, such as DIPEA, triethylamine, dimethylaniline, pyridine, quinoline, diazabicycloundecen (DBU) or di-isopropylethylamine (HOnig's base). Most preferably the reaction is carried out in the presence of triethylamine, DBU or di-isopropylethylam me.
Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -30 and 1400, normally between -100 and 90 , in particular between about 0 and about 40 .
The reaction preferably is carried in an inert solvent.
Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chlo-roform or dichloromethane; alcohols, such as methanol, ethanol, isopropa-nol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMS0); carbon di-sulfide; carboxylic acids, such as formic acid or acetic acid; nitro com-pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace-tate, or mixtures of the said solvents.
/ / /
PRIOR ART
Prior art references WO 2012/048775, WO 2013/149704 and WO 2016020031 disclose a racemic synthesis for manufacturing the racemic compound followed by chiral separation.
(S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide is disclosed as "B8" in WO 2013/149704.
SUMMARY OF THE INVENTION
The invention relates to a process for manufacturing (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide ("S-9"), characterized in that a) 2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-yl)pyrrolidine-3-carboxylic acid ("5") is reacted with 3,5-difluorobenzyl amine to give 1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-2-oxopyrrolidine-3-carboxamide ("12"), b) "12" is then enantioselectively oxidized to give (3S)-1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-3-hydroxy-2-oxopyrrolidine-3-carboxamide ("13"), c) and subsequently the phenylsulfonyl group is cleaved off from "13" to give (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylam ide ("S-9").
Preferably the invention relates to a process for manufacturing (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide ("S-9"), characterized in that 2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-yl)pyrrolidine-3-carboxylic acid ("5") is reacted with 3,5-difluorobenzyl amine to give 1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-2-oxopyrrolidine-3-carboxamide ("12"), "12" is then reacted with (+)-(2R,4aS,7S,8aR)-4H-4a, 7-methanooxazirino[3, 2-i] [2, 1] benzisothiazole, 8,8-dichlorotetrahydro-9,9-dimethy1-3,3-dioxide to give (3S)-1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-3-hydroxy-2-oxopyrrolidine-3-carboxamide ("13"), and subsequently the phenylsulfonyl group is cleaved off from "13" to give (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide ("S-9").
The reaction of compound 5 with 3,5-difluorobenzyl amine in step 4C is generally carried out in the presence of an a organic base, such as DIPEA, triethylamine, dimethylaniline, pyridine, quinoline, diazabicycloundecen (DBU) or di-isopropylethylamine (HOnig's base). Most preferably the reaction is carried out in the presence of triethylamine, DBU or di-isopropylethylam me.
Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -30 and 1400, normally between -100 and 90 , in particular between about 0 and about 40 .
The reaction preferably is carried in an inert solvent.
Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chlo-roform or dichloromethane; alcohols, such as methanol, ethanol, isopropa-nol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMS0); carbon di-sulfide; carboxylic acids, such as formic acid or acetic acid; nitro com-pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace-tate, or mixtures of the said solvents.
- 6 -Particular preference is given to acetonitrile, dichloromethane and/or DMF, particularly preferred is dichloromethane.
The amide coupling of of compound 5 with 3,5-difluorobenzyl amine preferably is carried out in the presence of T3P (propanephosphonic acid anhydride).
Other preferred acid activating compounds are as follows, such as carbodiim ides:
EDC1(1-ethy1-3-(3-dimethylaminopropyl)carbodiimide), DCC (dicyclohexylcarbodiimide);
phosphonium salts:
BOP (benzotriazolyloxytris(dimethylamino)-phosphonium hexafluorophosphate), PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium-hexafluorophosphat);
Immonium salts are described by So-Yeop Han, Young-Ah Kim: Recent development of peptide coupling reagents in organic synthesis:
Tetrahedron 60, 2004, S. 2447;
Aminium salts:
HATU: 0-(7-azabenzotriazol-1-y1)-N,N,N',N'-tetramethyluronium-hexafluorphosphate;
HBTU (2-(1H-Benzotriazol-1-y1)-1 ,1,3,3-tetramethyluronium-hexafluorophosphate);
Uronium salts:
COMU ((1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylam ino-morpholino-carbenium-hexafluorophosphate);
Imidazolium salts:
Imidazolium salts are described by So-Yeop Han, Young-Ah Kim: Recent development of peptide coupling reagents in organic synthesis:
Tetrahedron 60, 2004, S. 2447;
The amide coupling of of compound 5 with 3,5-difluorobenzyl amine preferably is carried out in the presence of T3P (propanephosphonic acid anhydride).
Other preferred acid activating compounds are as follows, such as carbodiim ides:
EDC1(1-ethy1-3-(3-dimethylaminopropyl)carbodiimide), DCC (dicyclohexylcarbodiimide);
phosphonium salts:
BOP (benzotriazolyloxytris(dimethylamino)-phosphonium hexafluorophosphate), PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium-hexafluorophosphat);
Immonium salts are described by So-Yeop Han, Young-Ah Kim: Recent development of peptide coupling reagents in organic synthesis:
Tetrahedron 60, 2004, S. 2447;
Aminium salts:
HATU: 0-(7-azabenzotriazol-1-y1)-N,N,N',N'-tetramethyluronium-hexafluorphosphate;
HBTU (2-(1H-Benzotriazol-1-y1)-1 ,1,3,3-tetramethyluronium-hexafluorophosphate);
Uronium salts:
COMU ((1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylam ino-morpholino-carbenium-hexafluorophosphate);
Imidazolium salts:
Imidazolium salts are described by So-Yeop Han, Young-Ah Kim: Recent development of peptide coupling reagents in organic synthesis:
Tetrahedron 60, 2004, S. 2447;
- 7 -HObt (Hydroxybenzotriazole).
The oxidation of compound 12 to compound 13 in step C5 preferably is carried out in an organic solvent such as THF or diethylether.
The reaction generally is carried out in the presence of a base, such as NaHMDS (sodium-hexamethyldisilazane), LiHMDS (lithium-hexamethyldisilazane), KHMDS (potassium-hexamethyldisilazane), LDA
(lithium diisopropylamide), BuLi (buthyl lithium) or potassium tert.butylate.
Particular preference is given to NaHMDS.
The reaction is preferably carried out with the asymmetric oxidation reagent (+)-(2R,4aS,7S,8aR)-4H-4a, 7-Methanooxazirino[3, 2-i] [2, 1]
benzisothiazole, 8,8-dichlorotetrahydro-9,9-dimethy1-3,3-dioxide ci cifl N.
k 0S.
Instead of the dichloro compound the dibromo or difluoro compounds are preferred.
The reaction of compound 13 to compound S-9 (cleavage of the phenylsulfonyl group) in step C6 most preferably is carried out with an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali or alkaline earth metals, preferably of potassium, sodium, calcium or caesium, may also be favourable.
The reaction preferably is carried in an inert solvent.
Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -30 and
The oxidation of compound 12 to compound 13 in step C5 preferably is carried out in an organic solvent such as THF or diethylether.
The reaction generally is carried out in the presence of a base, such as NaHMDS (sodium-hexamethyldisilazane), LiHMDS (lithium-hexamethyldisilazane), KHMDS (potassium-hexamethyldisilazane), LDA
(lithium diisopropylamide), BuLi (buthyl lithium) or potassium tert.butylate.
Particular preference is given to NaHMDS.
The reaction is preferably carried out with the asymmetric oxidation reagent (+)-(2R,4aS,7S,8aR)-4H-4a, 7-Methanooxazirino[3, 2-i] [2, 1]
benzisothiazole, 8,8-dichlorotetrahydro-9,9-dimethy1-3,3-dioxide ci cifl N.
k 0S.
Instead of the dichloro compound the dibromo or difluoro compounds are preferred.
The reaction of compound 13 to compound S-9 (cleavage of the phenylsulfonyl group) in step C6 most preferably is carried out with an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali or alkaline earth metals, preferably of potassium, sodium, calcium or caesium, may also be favourable.
The reaction preferably is carried in an inert solvent.
Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -30 and
8 PCT/EP2020/068317 1400, normally between -100 and 90 , in particular between about 0 and about 70 .
Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chlo-roform or dichloromethane; alcohols, such as methanol, ethanol, isopropa-nol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMS0); carbon di-sulfide; carboxylic acids, such as formic acid or acetic acid; nitro com-pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace-tate, or mixtures of the said solvents.
Particular preference is given to ethanol and/or THF.
The reaction of compound 13 to compound S-9 (cleavage of the phenylsulfonyl group) in step C6 most preferably is carried out with NaOH in a mixture of ethanol/THF.
More preferably, the cleavage of the phenyl sulfonyl group from the indole ring is carried out as follows:
with tetrabutyl ammonium fluoride in THF;
with magnesium or lithium tert.butoxide in THF;
with sodium tert.butylate in dioxane;
with 1-(N,N-dimethylamino)pyrene, triethylamine in acetonitrile;
with titanium(IV)isopropylate, chloro-trimethyl-silane, magnesium in THF.
Examples
Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chlo-roform or dichloromethane; alcohols, such as methanol, ethanol, isopropa-nol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMS0); carbon di-sulfide; carboxylic acids, such as formic acid or acetic acid; nitro com-pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace-tate, or mixtures of the said solvents.
Particular preference is given to ethanol and/or THF.
The reaction of compound 13 to compound S-9 (cleavage of the phenylsulfonyl group) in step C6 most preferably is carried out with NaOH in a mixture of ethanol/THF.
More preferably, the cleavage of the phenyl sulfonyl group from the indole ring is carried out as follows:
with tetrabutyl ammonium fluoride in THF;
with magnesium or lithium tert.butoxide in THF;
with sodium tert.butylate in dioxane;
with 1-(N,N-dimethylamino)pyrene, triethylamine in acetonitrile;
with titanium(IV)isopropylate, chloro-trimethyl-silane, magnesium in THF.
Examples
- 9 -Step-1: 3 [5-nitro-1-(phenylsulfony1)-1H-indole]
Reaction scheme:
NO2 ci NO2 (:),A*0 HN N
Oz-.e *0 162.04 175.97 302.04 Experimental procedure:
5-nitro indole 1 (500 g, 3.08 mol) was dissolved in THF (5 L) and the mixture was cooled to 0 C and stirred for 20 minutes. Sodium hydride (140 g, 3.5 mol) was added in portions and the mixture was stirred for additional 30 minutes at C. Benzene sulphonyl chloride 2 (475 mL, 3.7 mol) was introduced through an additional funnel for 30 minutes under stirring. After completion of the addition the mixture was stirred for 4 hours. After completion of the reaction, the reaction mass was cooled to 0 C and quenched with ice (3 L). Ethyl acetate (5 L) and water (2.5 L) were added. After phase separation the aqueous layer was re-extracted with ethyl acetate (5 L). The combined organic layer was dried over sodium sulphate and concentrated under reduced pressure at 55 C. Ethyl acetate/pet. ether (8%, 5 L) were added to the crude mass and the mixture was stirred for 20 min at room temperature. The product was filtered and washed with ethyl acetate and pet. ether mixture (5%, 2 L).
The product was dried under vacuum to give 3 as a yellow solid.
Yield 890 g (95%).
Reaction scheme:
NO2 ci NO2 (:),A*0 HN N
Oz-.e *0 162.04 175.97 302.04 Experimental procedure:
5-nitro indole 1 (500 g, 3.08 mol) was dissolved in THF (5 L) and the mixture was cooled to 0 C and stirred for 20 minutes. Sodium hydride (140 g, 3.5 mol) was added in portions and the mixture was stirred for additional 30 minutes at C. Benzene sulphonyl chloride 2 (475 mL, 3.7 mol) was introduced through an additional funnel for 30 minutes under stirring. After completion of the addition the mixture was stirred for 4 hours. After completion of the reaction, the reaction mass was cooled to 0 C and quenched with ice (3 L). Ethyl acetate (5 L) and water (2.5 L) were added. After phase separation the aqueous layer was re-extracted with ethyl acetate (5 L). The combined organic layer was dried over sodium sulphate and concentrated under reduced pressure at 55 C. Ethyl acetate/pet. ether (8%, 5 L) were added to the crude mass and the mixture was stirred for 20 min at room temperature. The product was filtered and washed with ethyl acetate and pet. ether mixture (5%, 2 L).
The product was dried under vacuum to give 3 as a yellow solid.
Yield 890 g (95%).
- 10 -1H NMR (400 MHz, DMSO-de) 6 8.63 -8.55 (m, 1 H), 8.26 - 8.14 (m, 2 H), 8.13 - 8.02 (m, 3 H), 7.79 - 7.70 (m, 1 H), 7.69 - 7.59 (m, 2 H), 7.10 (d, J =
3.7 Hz, 1 H); Molecular Formula: Ci4HioN204S; HPLC purity: 99.92%; Expected LCMS Mass: 302.0; Observed: 161.2 (M-141).
Step-2: 4 1-(phenylsulfony1)-1H-indol-5-am ine Reaction scheme:
310.-N N
Ozze *0 3 *0 302.04 272.06 Experimental procedure:
Step-1 product 3 (500 g, 1.65 mol) was dissolved in ethanol (7 L). Iron powder was added (500 g, 8.95 mol) and the mixture was heated to 50 C. After 15 minutes, a solution of NH4C1 (1 kg, 18.69 mol) in water (3.1 L) was added to the reaction mixture through an additional funnel for 1 hour. The reaction mixture was heated to 80 C for 2 hours. After completion of the reaction, the reaction mass was cooled to 40 C, filtered through celite and concentrated under reduced pressure at 50 C. Ethyl acetate and water (5 L each) were added and the layers were separated. The aq. layer was re-extracted with ethyl acetate (5 L). The combined organic layer was dried over sodium sulphate and concentrated under reduced pressure at 50 C. The reminder was suspended in ethyl acetate/pet. ether (5%, 5 L) and then cooled to room temperature. The product was filtered and washed with ethyl acetate/pet. ether (5%, 5 L). The product was dried under vacuum to give 4 as a brown solid.
3.7 Hz, 1 H); Molecular Formula: Ci4HioN204S; HPLC purity: 99.92%; Expected LCMS Mass: 302.0; Observed: 161.2 (M-141).
Step-2: 4 1-(phenylsulfony1)-1H-indol-5-am ine Reaction scheme:
310.-N N
Ozze *0 3 *0 302.04 272.06 Experimental procedure:
Step-1 product 3 (500 g, 1.65 mol) was dissolved in ethanol (7 L). Iron powder was added (500 g, 8.95 mol) and the mixture was heated to 50 C. After 15 minutes, a solution of NH4C1 (1 kg, 18.69 mol) in water (3.1 L) was added to the reaction mixture through an additional funnel for 1 hour. The reaction mixture was heated to 80 C for 2 hours. After completion of the reaction, the reaction mass was cooled to 40 C, filtered through celite and concentrated under reduced pressure at 50 C. Ethyl acetate and water (5 L each) were added and the layers were separated. The aq. layer was re-extracted with ethyl acetate (5 L). The combined organic layer was dried over sodium sulphate and concentrated under reduced pressure at 50 C. The reminder was suspended in ethyl acetate/pet. ether (5%, 5 L) and then cooled to room temperature. The product was filtered and washed with ethyl acetate/pet. ether (5%, 5 L). The product was dried under vacuum to give 4 as a brown solid.
- 11 -Yield 400 g (89%).
1H NMR (300 MHz, DMSO-de) 6 7.86 (d, J = 7.5 Hz, 2 H), 7.70 - 7.42 (m, 5 H), 6.67 - 6.48 (m, 3 H), 4.97 (s, 2 H); Molecular Formula: Ci4Hi2N202S; HPLC
purity: 97.25%; Expected LCMS Mass: 272.1; Observed: 273.0 (M + 1).
Step-3: 5 2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-yl)pyrrolidine-3-carboxylic acid Reaction Scheme:
/ + ORrO
Ox0 *0 N
4 %% 5 *0 272.06 170.06 384.08 Experimental procedure:
Step-2 product 4 (1.6 kg, 5.87 mol) and cyclopropyl meldrum acid (1.2 kg, 7.05 mol) were given into the reactor followed by acetonitrile (5.5 L) and DMF (1.9 L). The mixture was heated to 70 C for 16 hours under nitrogen atmosphere.
After completion of the reaction, the reaction mass was concentrated under reduced pressure at 50-55 C. The residue was cooled and treated with water and ethyl acetate (10 L each). After phase separation the organic layer was washed with brine (5 L), dried over sodium sulphate and concentrated under reduced pressure at 40-45 C. The obtained crude solid was washed with ethyl acetate/pet. ether (5%, 2 L) giving 5 as brown solid.
1H NMR (300 MHz, DMSO-de) 6 7.86 (d, J = 7.5 Hz, 2 H), 7.70 - 7.42 (m, 5 H), 6.67 - 6.48 (m, 3 H), 4.97 (s, 2 H); Molecular Formula: Ci4Hi2N202S; HPLC
purity: 97.25%; Expected LCMS Mass: 272.1; Observed: 273.0 (M + 1).
Step-3: 5 2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-yl)pyrrolidine-3-carboxylic acid Reaction Scheme:
/ + ORrO
Ox0 *0 N
4 %% 5 *0 272.06 170.06 384.08 Experimental procedure:
Step-2 product 4 (1.6 kg, 5.87 mol) and cyclopropyl meldrum acid (1.2 kg, 7.05 mol) were given into the reactor followed by acetonitrile (5.5 L) and DMF (1.9 L). The mixture was heated to 70 C for 16 hours under nitrogen atmosphere.
After completion of the reaction, the reaction mass was concentrated under reduced pressure at 50-55 C. The residue was cooled and treated with water and ethyl acetate (10 L each). After phase separation the organic layer was washed with brine (5 L), dried over sodium sulphate and concentrated under reduced pressure at 40-45 C. The obtained crude solid was washed with ethyl acetate/pet. ether (5%, 2 L) giving 5 as brown solid.
- 12 -Yield: 1.8 kg (80%).
1H NMR (300 MHz, DMSO-de) 6 12.80 (br. s., 1 H), 8.02 - 7.85 (m, 3 H), 7.85 -7.74 (m, 2 H), 7.71 - 7.47 (m, 4 H), 6.84 (d, J = 3.6 Hz, 1 H), 3.94 - 3.76 (m, 2 H), 3.57 (t, J = 8.5 Hz, 1 H), 2.37 - 2.20 (m, 2 H); Molecular Formula:
C19H16N205S; HPLC purity: 91.51%; Expected LCMS Mass: 384.08;
Observed: 385.0 (M + 1).
5 is the starting point for both procedures, the racemic and the asymmetric syntheses.
Step-4: 6 3-hydroxy-2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-yl)pyrrolidine-3-carboxylic acid Reaction scheme:
tOH HOri MMPP
N N
Oz.-s' 0:s' 384.08 400.07 Experimental procedure:
Step-3 product 5 (1.0 kg, 2.60 mol) was treated with DMF (8.5 L) and Magnesium monoperoxyphthalate hexahydrate 80% (1.9 kg, 3.84 mol). The mixture was heated to 60 C for 2 hours under nitrogen atmosphere. After completion of the reaction, the reaction mass was concentrated under reduced
1H NMR (300 MHz, DMSO-de) 6 12.80 (br. s., 1 H), 8.02 - 7.85 (m, 3 H), 7.85 -7.74 (m, 2 H), 7.71 - 7.47 (m, 4 H), 6.84 (d, J = 3.6 Hz, 1 H), 3.94 - 3.76 (m, 2 H), 3.57 (t, J = 8.5 Hz, 1 H), 2.37 - 2.20 (m, 2 H); Molecular Formula:
C19H16N205S; HPLC purity: 91.51%; Expected LCMS Mass: 384.08;
Observed: 385.0 (M + 1).
5 is the starting point for both procedures, the racemic and the asymmetric syntheses.
Step-4: 6 3-hydroxy-2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-yl)pyrrolidine-3-carboxylic acid Reaction scheme:
tOH HOri MMPP
N N
Oz.-s' 0:s' 384.08 400.07 Experimental procedure:
Step-3 product 5 (1.0 kg, 2.60 mol) was treated with DMF (8.5 L) and Magnesium monoperoxyphthalate hexahydrate 80% (1.9 kg, 3.84 mol). The mixture was heated to 60 C for 2 hours under nitrogen atmosphere. After completion of the reaction, the reaction mass was concentrated under reduced
- 13 -pressure at 50-55 C. The residue was taken in water (5 L) and ethyl acetate (3 L) and stirred for 12 hours at room temperature. The product was filtered and washed with water and ethyl acetate (3 L each). The product was dried under vacuum at 65 C to give 6 as off white solid.
Yield: 700 g (67%).
Note: Moisture content of the step 4 product should be less than 0.5%.
1H NMR (400 MHz, DMSO-de) 6 7.97 - 7.94 (m, 3 H), 7.87 (s, 1 H), 7.81 ¨
7.80 (d, J = 3.4 Hz, 1H), 7.73 - 7.66 (m, 2 H), 7.60 - 7.56 (m, 2 H), 7.16 (brs, 1H), 6.87 (d, J = 3.4 Hz, 1 H), 3.92 (q, J = 8.4 Hz, 1 H), 3.75 (t, J = 8.7 Hz, 1 H), 3.45 ¨ 3.42 (m, 1H), 2.43 ¨ 2.38 (m, 1 H), 2.03 - 1.96 (m, 1 H); Molecular Formula: C19H16N206S; HPLC purity: 96.12%; Expected LCMS Mass: 400.07;
Observed: 401.0 (M + 1).
Step-5: 7 3-acetoxy-2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-y1) pyrrolidine - 3-carboxylic acid Reaction scheme:
HOri )-0 Ac20 Otts' CozzsiN
*0 6 0 400.07 442.08
Yield: 700 g (67%).
Note: Moisture content of the step 4 product should be less than 0.5%.
1H NMR (400 MHz, DMSO-de) 6 7.97 - 7.94 (m, 3 H), 7.87 (s, 1 H), 7.81 ¨
7.80 (d, J = 3.4 Hz, 1H), 7.73 - 7.66 (m, 2 H), 7.60 - 7.56 (m, 2 H), 7.16 (brs, 1H), 6.87 (d, J = 3.4 Hz, 1 H), 3.92 (q, J = 8.4 Hz, 1 H), 3.75 (t, J = 8.7 Hz, 1 H), 3.45 ¨ 3.42 (m, 1H), 2.43 ¨ 2.38 (m, 1 H), 2.03 - 1.96 (m, 1 H); Molecular Formula: C19H16N206S; HPLC purity: 96.12%; Expected LCMS Mass: 400.07;
Observed: 401.0 (M + 1).
Step-5: 7 3-acetoxy-2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-y1) pyrrolidine - 3-carboxylic acid Reaction scheme:
HOri )-0 Ac20 Otts' CozzsiN
*0 6 0 400.07 442.08
- 14 -Experimental procedure:
Step-4 product 6 (1.0 kg, 2.5 mol) and DMF (8 L) were given into a reactor at room temperature and stirred for 10 minutes. Acetic anhydride (355 mL, 3.75 mol) was added slowly to the mass and the mixture was stirred for 12 hours.
After completion of the reaction, the reaction mass was concentrated under reduced pressure at 50-55 C. The residue was cooled to 0 C, suspended with water (5 L) and stirred for overnight at room temperature. The precipitate was filtered, washed with water (3 L) and then suspended in acetone (3 L) for 1 hour. Filtration gave product 7 as white solid, which was dried under vacuum at 65 C.
Yield: 940 g (85%).
Note: Moisture content of the step 5 product should be less than 0.5%.
1H NMR (400 MHz, DMSO-de) 6 7.98 - 7.89 (m, 3 H), 7.86 - 7.77 (m, 2 H), 7.73 - 7.62 (m, 2 H), 7.60 - 7.51 (m, 2 H), 6.85 (d, J = 3.8 Hz, 1 H), 3.98 (q, J =
8.1 Hz, 1 H), 3.72 (t, J = 9.0 Hz, 1 H), 2.79 (dd, J = 7.3, 12.1 Hz, 1 H), 2.22 -2.09 (m, 1 H), 2.01 (s, 3 H); Molecular Formula: C21 Hi8N207S; HPLC purity:
97.83%; Expected LCMS Mass: 442.08; Observed: 443.0 (M + 1).
NB:
Reaction mixture should be concentrated below 55 C and evaporation should be complete within 2 hours. Higher temperature and prolong heating leads to de-carboxylation of the product.
Step-6: 8 3-((3,5-difluorobenzyl)carbamoyI)-2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-Apyrrolidin-3-y1 acetate.
Reaction scheme:
Step-4 product 6 (1.0 kg, 2.5 mol) and DMF (8 L) were given into a reactor at room temperature and stirred for 10 minutes. Acetic anhydride (355 mL, 3.75 mol) was added slowly to the mass and the mixture was stirred for 12 hours.
After completion of the reaction, the reaction mass was concentrated under reduced pressure at 50-55 C. The residue was cooled to 0 C, suspended with water (5 L) and stirred for overnight at room temperature. The precipitate was filtered, washed with water (3 L) and then suspended in acetone (3 L) for 1 hour. Filtration gave product 7 as white solid, which was dried under vacuum at 65 C.
Yield: 940 g (85%).
Note: Moisture content of the step 5 product should be less than 0.5%.
1H NMR (400 MHz, DMSO-de) 6 7.98 - 7.89 (m, 3 H), 7.86 - 7.77 (m, 2 H), 7.73 - 7.62 (m, 2 H), 7.60 - 7.51 (m, 2 H), 6.85 (d, J = 3.8 Hz, 1 H), 3.98 (q, J =
8.1 Hz, 1 H), 3.72 (t, J = 9.0 Hz, 1 H), 2.79 (dd, J = 7.3, 12.1 Hz, 1 H), 2.22 -2.09 (m, 1 H), 2.01 (s, 3 H); Molecular Formula: C21 Hi8N207S; HPLC purity:
97.83%; Expected LCMS Mass: 442.08; Observed: 443.0 (M + 1).
NB:
Reaction mixture should be concentrated below 55 C and evaporation should be complete within 2 hours. Higher temperature and prolong heating leads to de-carboxylation of the product.
Step-6: 8 3-((3,5-difluorobenzyl)carbamoyI)-2-oxo-1-(1-(phenylsulfony1)-1H-indol-5-Apyrrolidin-3-y1 acetate.
Reaction scheme:
- 15 -yo).--OH NH
H2N 0 Ni 110 *
N F
*07 o8 C21HigN207S C7H7F2N C281-123F2N306S
442.08 143.05 567.13 Experimental procedure:
Step-5 product 7 (1.0 kg, 2.26 mol) was dissolved in CH2Cl2 (10 L) at room temperature for 10 minutes and then cooled to 0 C. Triethyl amine (690 mL, 4.95 mol), 3,5-difluorobenzyl amine (405 g, 2.83 mol) and 2,4,6-tripropyl-[1,3,5,2,4,6]trioxatriphosphinane 2,4,6-trioxide (2.15 L, 3.38 mol) were added and the reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mass was diluted with water (5 L) and stirred for 10 minutes. The aqueous layer was removed from the top. This aqueous washing was repeated 3 times. The organic layer was filtered and the precipitate was washed with CH2Cl2 (1 L) and acetone (0.5 L) to get 8 as off white solid.
Yield: 1.07 kg (83%).
1H NMR (400 MHz, DMSO-de) 6 8.99 (t, J = 6.2 Hz, 1 H), 7.97 (d, J = 8.1 Hz, 3 H), 7.83 (dd, J = 2.8, 5.2 Hz, 2 H), 7.72 - 7.63 (m, 2 H), 7.62 - 7.53 (m, 2 H), 7.06 (t, J = 9.4 Hz, 1 H), 6.93 (d, J = 7.0 Hz, 2 H), 6.87 (d, J = 3.5 Hz, 1 H), 4.33 (dq, J = 6.0, 16.1 Hz, 2 H), 3.99 -3.83 (m, 2 H), 2.88 (ddd, J = 2.6, 7.9,
H2N 0 Ni 110 *
N F
*07 o8 C21HigN207S C7H7F2N C281-123F2N306S
442.08 143.05 567.13 Experimental procedure:
Step-5 product 7 (1.0 kg, 2.26 mol) was dissolved in CH2Cl2 (10 L) at room temperature for 10 minutes and then cooled to 0 C. Triethyl amine (690 mL, 4.95 mol), 3,5-difluorobenzyl amine (405 g, 2.83 mol) and 2,4,6-tripropyl-[1,3,5,2,4,6]trioxatriphosphinane 2,4,6-trioxide (2.15 L, 3.38 mol) were added and the reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mass was diluted with water (5 L) and stirred for 10 minutes. The aqueous layer was removed from the top. This aqueous washing was repeated 3 times. The organic layer was filtered and the precipitate was washed with CH2Cl2 (1 L) and acetone (0.5 L) to get 8 as off white solid.
Yield: 1.07 kg (83%).
1H NMR (400 MHz, DMSO-de) 6 8.99 (t, J = 6.2 Hz, 1 H), 7.97 (d, J = 8.1 Hz, 3 H), 7.83 (dd, J = 2.8, 5.2 Hz, 2 H), 7.72 - 7.63 (m, 2 H), 7.62 - 7.53 (m, 2 H), 7.06 (t, J = 9.4 Hz, 1 H), 6.93 (d, J = 7.0 Hz, 2 H), 6.87 (d, J = 3.5 Hz, 1 H), 4.33 (dq, J = 6.0, 16.1 Hz, 2 H), 3.99 -3.83 (m, 2 H), 2.88 (ddd, J = 2.6, 7.9,
- 16 -13.2 Hz, 1 H), 2.43 - 2.28 (m, 1 H), 2.18 (s, 3 H); Molecular Formula:
C28H23F2N306S; HPLC purity: 99.88%; Expected LCMS Mass: 567.13;
Observed: 568.0 (M + 1).
Step-7: 9 N-(3, 5-difluorobenzy1)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxopyrrolidine-3-carboxamide Reaction scheme:
H
N
H
Oy=
9 0, N
NS', 8 HN
567.13 385.12 Experimental procedure:
Step-6 product 8 (1.2 kg, 2.11 mol) was dissolved in ethanol (5 L) and THF (10 L) and stirred at room temperature for 10 minutes. Sodium hydroxide (422 g, 10.55 mol) was added and stirred for 2 hours at 50 C. After completion of the reaction, the reaction mass was concentrated under reduced pressure at 45 C. The residue was dissolved in ethyl acetate (10 L) and water (5 L). After phase separation the organic layer was washed with water (2 x 5 L) and brine (5 L). The organic layer was dried over sodium sulphate, filtered and concentrated under reduced pressure at 45-50 C. CH2Cl2 (1 L) was added to the reminder and the precipitate was filtered and washed with CH2Cl2 (1.0 L) to give 9 as off white solid.
C28H23F2N306S; HPLC purity: 99.88%; Expected LCMS Mass: 567.13;
Observed: 568.0 (M + 1).
Step-7: 9 N-(3, 5-difluorobenzy1)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxopyrrolidine-3-carboxamide Reaction scheme:
H
N
H
Oy=
9 0, N
NS', 8 HN
567.13 385.12 Experimental procedure:
Step-6 product 8 (1.2 kg, 2.11 mol) was dissolved in ethanol (5 L) and THF (10 L) and stirred at room temperature for 10 minutes. Sodium hydroxide (422 g, 10.55 mol) was added and stirred for 2 hours at 50 C. After completion of the reaction, the reaction mass was concentrated under reduced pressure at 45 C. The residue was dissolved in ethyl acetate (10 L) and water (5 L). After phase separation the organic layer was washed with water (2 x 5 L) and brine (5 L). The organic layer was dried over sodium sulphate, filtered and concentrated under reduced pressure at 45-50 C. CH2Cl2 (1 L) was added to the reminder and the precipitate was filtered and washed with CH2Cl2 (1.0 L) to give 9 as off white solid.
- 17 -Yield: 700 g (86%).
1H NMR (400 MHz, DMSO-de) 6 11.12 (br. s., 1 H), 8.69 (t, J = 6.4 Hz, 1 H), 7.70 (s, 1 H), 7.46 -7.32 (m, 3 H), 7.12 -6.94 (m, 3 H), 6.69 (s, 1 H), 6.47 -6.38 (m, 1 H), 4.41 (dd, J = 6.9, 16.0 Hz, 1 H), 4.25 (dd, J = 5.9, 15.8 Hz, 1 H), 3.94 - 3.81 (m, 2 H), 2.66 - 2.54 (m, 1 H), 2.13 (td, J = 7.6, 13.0 Hz, 1 H);
Molecular Formula: C20H17F2N303; HPLC purity: 98.11%; Expected LCMS
Mass: 385.12; Observed: 386.0 (M + 1).
SFC separation:
Isomers of 9 (5.20 Kg) were separated via SFC purification.
SFC Method:
Column : Lux Amylose-2 (250 X 30) mm, 5 micron Mobile phase : CO2: Me0H (60:40) Flow rate : 200 g/min Run time : 10 min (cycle time) Loading per injection : 700 mg Quantity Quantity Output input S-9 (Fraction 1) Mixture of R-9 (Fraction 2) 9 fraction 1 & 2 5.20 Kg 1.93 Kg 0.60 Kg 1.80 Kg (37%) Fraction 1 (S-9): 1H NMR (400 MHz, DMSO-de) 6 11.12 (br. s., 1 H), 8.69 (t, J
= 6.4 Hz, 1 H), 7.70 (s, 1 H), 7.46 - 7.32 (m, 3 H), 7.12 -6.94 (m, 3 H), 6.69 (s, 1 H), 6.47 -6.38 (m, 1 H), 4.41 (dd, J = 6.9, 16.0 Hz, 1 H), 4.25 (dd, J =
5.9, 15.8 Hz, 1 H), 3.94 - 3.81 (m, 2 H), 2.66 - 2.54 (m, 1 H), 2.13 (td, J = 7.6, 13.0 Hz, 1 H); Molecular Formula: C20H17F2N303; HPLC purity: 99.46%; Chiral HPLC purity: 100%; Expected LCMS Mass: 385.12; Observed: 386.0 (M + 1);
SOR: +14.69.
1H NMR (400 MHz, DMSO-de) 6 11.12 (br. s., 1 H), 8.69 (t, J = 6.4 Hz, 1 H), 7.70 (s, 1 H), 7.46 -7.32 (m, 3 H), 7.12 -6.94 (m, 3 H), 6.69 (s, 1 H), 6.47 -6.38 (m, 1 H), 4.41 (dd, J = 6.9, 16.0 Hz, 1 H), 4.25 (dd, J = 5.9, 15.8 Hz, 1 H), 3.94 - 3.81 (m, 2 H), 2.66 - 2.54 (m, 1 H), 2.13 (td, J = 7.6, 13.0 Hz, 1 H);
Molecular Formula: C20H17F2N303; HPLC purity: 98.11%; Expected LCMS
Mass: 385.12; Observed: 386.0 (M + 1).
SFC separation:
Isomers of 9 (5.20 Kg) were separated via SFC purification.
SFC Method:
Column : Lux Amylose-2 (250 X 30) mm, 5 micron Mobile phase : CO2: Me0H (60:40) Flow rate : 200 g/min Run time : 10 min (cycle time) Loading per injection : 700 mg Quantity Quantity Output input S-9 (Fraction 1) Mixture of R-9 (Fraction 2) 9 fraction 1 & 2 5.20 Kg 1.93 Kg 0.60 Kg 1.80 Kg (37%) Fraction 1 (S-9): 1H NMR (400 MHz, DMSO-de) 6 11.12 (br. s., 1 H), 8.69 (t, J
= 6.4 Hz, 1 H), 7.70 (s, 1 H), 7.46 - 7.32 (m, 3 H), 7.12 -6.94 (m, 3 H), 6.69 (s, 1 H), 6.47 -6.38 (m, 1 H), 4.41 (dd, J = 6.9, 16.0 Hz, 1 H), 4.25 (dd, J =
5.9, 15.8 Hz, 1 H), 3.94 - 3.81 (m, 2 H), 2.66 - 2.54 (m, 1 H), 2.13 (td, J = 7.6, 13.0 Hz, 1 H); Molecular Formula: C20H17F2N303; HPLC purity: 99.46%; Chiral HPLC purity: 100%; Expected LCMS Mass: 385.12; Observed: 386.0 (M + 1);
SOR: +14.69.
- 18 -Fraction 2 (R-9): 1H NMR (400 MHz, DMSO-de) 6 11.12 (br. s., 1 H), 8.69 (t, J
= 6.3 Hz, 1 H), 7.73 - 7.68 (m, 1 H), 7.45 -7.31 (m, 3 H), 7.11 -6.94 (m, 3 H), 6.69 (s, 1 H), 6.46 -6.38 (m, 1 H), 4.41 (dd, J = 6.7, 15.8 Hz, 1 H), 4.25 (dd, J
= 5.9, 15.8 Hz, 1 H), 3.94 - 3.79 (m, 2 H), 2.66 - 2.56 (m, 1 H), 2.13 (td, J
=
7.6, 13.0 Hz, 1 H); Molecular Formula: C20H17F2N303; HPLC purity: 97.20%;
Chiral HPLC purity: 98.17%; Expected LCMS Mass: 385.12; Observed: 386.2 (M + 1); SOR: -13.49.
Mixture of fraction (1 & 2): HPLC purity: 98.90%; Chiral HPLC purity: 32.99%
(fraction 1) & 67.01 (fraction 2).
Yield optimization can be achieved by inversion of the chiral centre. The invented procedure is outlined.
Step 8: 10 (R)-3-((3,5-difluorobenzyl)carbamoy1)-1-(1H-indo1-5-y1)-2-oxopyrrolidin-3-y1 methanesulfonate Reaction scheme:
0 0 S, OHi = HO
J) F
CH2Cl2 Step 8 HN HN
Experimental procedure:
To an ice cooled solution of R-9 (200 g, 0.52 mol) in dry CH2Cl2 (2 L), was added Et3N (252 ml, 1.81 mol) followed by drop wise addition of Mesyl chloride
= 6.3 Hz, 1 H), 7.73 - 7.68 (m, 1 H), 7.45 -7.31 (m, 3 H), 7.11 -6.94 (m, 3 H), 6.69 (s, 1 H), 6.46 -6.38 (m, 1 H), 4.41 (dd, J = 6.7, 15.8 Hz, 1 H), 4.25 (dd, J
= 5.9, 15.8 Hz, 1 H), 3.94 - 3.79 (m, 2 H), 2.66 - 2.56 (m, 1 H), 2.13 (td, J
=
7.6, 13.0 Hz, 1 H); Molecular Formula: C20H17F2N303; HPLC purity: 97.20%;
Chiral HPLC purity: 98.17%; Expected LCMS Mass: 385.12; Observed: 386.2 (M + 1); SOR: -13.49.
Mixture of fraction (1 & 2): HPLC purity: 98.90%; Chiral HPLC purity: 32.99%
(fraction 1) & 67.01 (fraction 2).
Yield optimization can be achieved by inversion of the chiral centre. The invented procedure is outlined.
Step 8: 10 (R)-3-((3,5-difluorobenzyl)carbamoy1)-1-(1H-indo1-5-y1)-2-oxopyrrolidin-3-y1 methanesulfonate Reaction scheme:
0 0 S, OHi = HO
J) F
CH2Cl2 Step 8 HN HN
Experimental procedure:
To an ice cooled solution of R-9 (200 g, 0.52 mol) in dry CH2Cl2 (2 L), was added Et3N (252 ml, 1.81 mol) followed by drop wise addition of Mesyl chloride
- 19 -(80.4 ml, 1.03 mol). The reaction mixture was stirred at the same temperature for another 2 hours. After completion, reaction mixture was washed with water (1.5 L), 5% Citric acid (1 L) and saturated aqueous solution of NaHCO3 (1 x 5 L). The combined organic extracts were washed with brine (1 L), dried over Na2SO4, filtered and concentrated under vacuum yielded 10 (260 g). The crude product was directly taken for next step without further purification.
Molecular Formula: C2+119F2N305S; HPLC purity: 81.76%; Expected LCMS
Mass: 463.10; Observed: 464.0 (M + 1).
Step 9:11 (S)-3-((3,5-difluorobenzyl)carbamoy1)-1-(1H-indo1-5-y1)-2-oxopyrrolidin-3-y1 acetate Reaction Scheme:
o, 0 ,Nsz F Cs0Ac F
HN '11 \NC; DMF HON) Step 9 HN HN
Experimental procedure:
To a solution of cesium acetate (214 g, 1.12 mol) in dry DMF (1.2 L) at 100 C
was added a solution of 10 (260 g, 0.560 mol) in DMF (1.0 L) dropwise over
Molecular Formula: C2+119F2N305S; HPLC purity: 81.76%; Expected LCMS
Mass: 463.10; Observed: 464.0 (M + 1).
Step 9:11 (S)-3-((3,5-difluorobenzyl)carbamoy1)-1-(1H-indo1-5-y1)-2-oxopyrrolidin-3-y1 acetate Reaction Scheme:
o, 0 ,Nsz F Cs0Ac F
HN '11 \NC; DMF HON) Step 9 HN HN
Experimental procedure:
To a solution of cesium acetate (214 g, 1.12 mol) in dry DMF (1.2 L) at 100 C
was added a solution of 10 (260 g, 0.560 mol) in DMF (1.0 L) dropwise over
20 minutes through an addition funnel. The heating was continued for another 1.5 hours. After completion, the reaction mass was concentrated under vacuum. The crude mass was dissolved in ethyl acetate (2 L) and washed with water (2 X 2 L). The combined organic extracts were washed with brine (1 L), dried over Na2SO4, filtered and concentrated under vacuum to yield 11(250 g). The crude product was directly taken for next step without further purification.
Molecular Formula: C22H19F2N304; HPLC purity: 45.64%; Expected LCMS
Mass427.13; Observed: 428.3 (M + 1).
Step 10: S-9 (S)-N-(3,5-difluorobenzy1)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxopyrrolidine-3-carboxam ide Reaction Scheme:
o cric )0H
F 40 NaOH
Me0H HO
40 Step 10 H
HN N
Experimental procedure:
To an ice cooled solution of the crude 11(250 g 0.52 mol) in methanol (2.5 L) was added NaOH pellets (63 g, 1.56 mol). The reaction mixture was stirred at RT for 2 hours. After completion, methanol was concentrated under vacuum at <55 C. The crude mass was dissolved in ethyl acetate (2 L) and washed with water (3 X 2 L). The combined organic extracts were washed with brine (1 L), dried over Na2SO4, filtered and concentrated under vacuum. It was passed through a wash column (Silica 60-120) and nonpolar impurities ware removed using 30-40% ethyl acetate/pet. ether. The product was eluted with 3-5%
Me0H/CH2C12. The isolated product was dissolved in minimum amount of ethyl acetate and kept in cold room for 16 hours. The solid formed was filtered
Molecular Formula: C22H19F2N304; HPLC purity: 45.64%; Expected LCMS
Mass427.13; Observed: 428.3 (M + 1).
Step 10: S-9 (S)-N-(3,5-difluorobenzy1)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxopyrrolidine-3-carboxam ide Reaction Scheme:
o cric )0H
F 40 NaOH
Me0H HO
40 Step 10 H
HN N
Experimental procedure:
To an ice cooled solution of the crude 11(250 g 0.52 mol) in methanol (2.5 L) was added NaOH pellets (63 g, 1.56 mol). The reaction mixture was stirred at RT for 2 hours. After completion, methanol was concentrated under vacuum at <55 C. The crude mass was dissolved in ethyl acetate (2 L) and washed with water (3 X 2 L). The combined organic extracts were washed with brine (1 L), dried over Na2SO4, filtered and concentrated under vacuum. It was passed through a wash column (Silica 60-120) and nonpolar impurities ware removed using 30-40% ethyl acetate/pet. ether. The product was eluted with 3-5%
Me0H/CH2C12. The isolated product was dissolved in minimum amount of ethyl acetate and kept in cold room for 16 hours. The solid formed was filtered
- 21 -through a BOchner funnel, washed with ethyl acetate (3 x 100 ml) to give S-9 (56 g, 28% in three steps) as off white solid.
Dried solid was milled in a pin mill (rpm 6000, 30 min) to obtain final API.
1H NMR (400 MHz, DMSO-de) 6 11.12 (br. s., 1 H), 8.69 (t, J = 6.4 Hz, 1 H), 7.70 (s, 1 H), 7.46 -7.32 (m, 3 H), 7.12 -6.94 (m, 3 H), 6.69 (s, 1 H), 6.47 -6.38 (m, 1 H), 4.41 (dd, J = 6.9, 16.0 Hz, 1 H), 4.25 (dd, J = 5.9, 15.8 Hz, 1 H), 3.94 - 3.81 (m, 2 H), 2.66 - 2.54 (m, 1 H), 2.13 (td, J = 7.6, 13.0 Hz, 1 H);
Molecular Formula: C20H17F2N303; HPLC purity: 98.72%; Chiral HPLC purity:
98.68%; (ee: 97.36%); Expected LCMS Mass: 385.12; Observed: 386.2 (M +
1).
Particle size : <18 pm.
SOR : +13.62.
MP : 195.3-198.9 C
MC :0.21%
RESIDUAL SOLVENTS:
Methanol ---------------- 17 ppm is Ethanol ND
ACN --------------------- ND
Ethyl acetate ---------- 75 ppm THF --------------------- 206 ppm n-Heptane --------------- 47 ppm Step-4C: 12 1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-2-oxopyrrolidine-3-carboxamide
Dried solid was milled in a pin mill (rpm 6000, 30 min) to obtain final API.
1H NMR (400 MHz, DMSO-de) 6 11.12 (br. s., 1 H), 8.69 (t, J = 6.4 Hz, 1 H), 7.70 (s, 1 H), 7.46 -7.32 (m, 3 H), 7.12 -6.94 (m, 3 H), 6.69 (s, 1 H), 6.47 -6.38 (m, 1 H), 4.41 (dd, J = 6.9, 16.0 Hz, 1 H), 4.25 (dd, J = 5.9, 15.8 Hz, 1 H), 3.94 - 3.81 (m, 2 H), 2.66 - 2.54 (m, 1 H), 2.13 (td, J = 7.6, 13.0 Hz, 1 H);
Molecular Formula: C20H17F2N303; HPLC purity: 98.72%; Chiral HPLC purity:
98.68%; (ee: 97.36%); Expected LCMS Mass: 385.12; Observed: 386.2 (M +
1).
Particle size : <18 pm.
SOR : +13.62.
MP : 195.3-198.9 C
MC :0.21%
RESIDUAL SOLVENTS:
Methanol ---------------- 17 ppm is Ethanol ND
ACN --------------------- ND
Ethyl acetate ---------- 75 ppm THF --------------------- 206 ppm n-Heptane --------------- 47 ppm Step-4C: 12 1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-2-oxopyrrolidine-3-carboxamide
- 22 -tOH
H F
F
N
Ark N21 384.08 143.05 509.12 Experimental procedure:
To an ice cooled solution of 5 (750 g, 1.95 mol) in CH2Cl2 (7 L), Et3N (600 mL, 4.29 mol) was added followed by 3,5-difluorobenzyl amine (363 g, 2.53 mol).
T3P (Propanephosphonic acid anhydride) (1.86 L (50% EA [ethyl acetate]
solution), 3.0 mol) was added dropwise into the reaction mixture slowly and the reaction mixture was stirred at RT for 2 h. After completion of the reaction, the reaction mass was quenched with water (3 L) and stirred for 10 minutes.
The organic layer was separated and washed with 10% NaHCO3 solution (2 L) followed by water wash (3L x 3). The organic phase was finally washed with brine (3L), dried over anhydrous sodium sulfate and concentrated to get the crude product as light brown solid. It was made slurry with minimum amount of ethyl acetate (1.5 L) and filtered. The cake was washed with ice cold ethyl acetate (1L x 2) to get the pure product as off white solid with HPLC >99%.
Amount obtained: 720 g; Yield: 72 %;
1H-NMR (400 MHz, DMSO-de): 6 8.82 (t, J = 5.60 Hz, 1H), 7.99-7.94 (m, 3H), 7.83 (d, J = 2.80 Hz, 2H), 7.71-7.67 (m, 2H), 7.61-7.57 (m, 2H), 7.12-7.05 (m, 3H), 6.87 (d, J = 3.60 Hz, 1H), 4.49 (dd, J = 6.80, 16.20 Hz, 1H), 4.27 (dd, J
=
H F
F
N
Ark N21 384.08 143.05 509.12 Experimental procedure:
To an ice cooled solution of 5 (750 g, 1.95 mol) in CH2Cl2 (7 L), Et3N (600 mL, 4.29 mol) was added followed by 3,5-difluorobenzyl amine (363 g, 2.53 mol).
T3P (Propanephosphonic acid anhydride) (1.86 L (50% EA [ethyl acetate]
solution), 3.0 mol) was added dropwise into the reaction mixture slowly and the reaction mixture was stirred at RT for 2 h. After completion of the reaction, the reaction mass was quenched with water (3 L) and stirred for 10 minutes.
The organic layer was separated and washed with 10% NaHCO3 solution (2 L) followed by water wash (3L x 3). The organic phase was finally washed with brine (3L), dried over anhydrous sodium sulfate and concentrated to get the crude product as light brown solid. It was made slurry with minimum amount of ethyl acetate (1.5 L) and filtered. The cake was washed with ice cold ethyl acetate (1L x 2) to get the pure product as off white solid with HPLC >99%.
Amount obtained: 720 g; Yield: 72 %;
1H-NMR (400 MHz, DMSO-de): 6 8.82 (t, J = 5.60 Hz, 1H), 7.99-7.94 (m, 3H), 7.83 (d, J = 2.80 Hz, 2H), 7.71-7.67 (m, 2H), 7.61-7.57 (m, 2H), 7.12-7.05 (m, 3H), 6.87 (d, J = 3.60 Hz, 1H), 4.49 (dd, J = 6.80, 16.20 Hz, 1H), 4.27 (dd, J
=
- 23 -5.20, 16.00 Hz, 1H), 3.90-3.85 (m, 2H), 3.63 (t, J = 8.80 Hz, 1H), 2.40-2.27 (m, 2H).
Step C5: 13 (3S)-1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-3-hydroxy-2-oxopyrrolidine-3-carboxamide H F H F
Orr\I 0 10 o, N 12 0, ,N 13 'S, c5 '0 c5 '0 509.12 525.12 Experimental procedure:
A suspension of 12 (500 g, 0.98 mol) in dry THF (7.5 L) was cooled to -68 C
(inside temperature). NaHMDS solution (1078 mL, 1M in THF, 1.078m01) was added drop wise over a period of 1.5 h while maintaining the same temperature range. After the complete addition, the reaction mixture temperature was allowed to rise to -55 C in another lh and then recooled to -68 C inside. To the yellow reaction mixture was added a solution of ((+)-(2R, 4aS, 7S, 8aR)-4H-4a, 7-methanooxazirino[3, 2-i] [2, 1] benzisothiazole, 8,8-dichlorotetrahydro-9,9-dimethy1-3,3-dioxide (365 g, 1.22 mol) in THF (1.1 L) dropwise over a period of 1.3 h at the same temperature. The reaction mass was allowed to come to -25 C in another 1.5h. After the complete
Step C5: 13 (3S)-1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3,5-difluorophenyl)methyl]-3-hydroxy-2-oxopyrrolidine-3-carboxamide H F H F
Orr\I 0 10 o, N 12 0, ,N 13 'S, c5 '0 c5 '0 509.12 525.12 Experimental procedure:
A suspension of 12 (500 g, 0.98 mol) in dry THF (7.5 L) was cooled to -68 C
(inside temperature). NaHMDS solution (1078 mL, 1M in THF, 1.078m01) was added drop wise over a period of 1.5 h while maintaining the same temperature range. After the complete addition, the reaction mixture temperature was allowed to rise to -55 C in another lh and then recooled to -68 C inside. To the yellow reaction mixture was added a solution of ((+)-(2R, 4aS, 7S, 8aR)-4H-4a, 7-methanooxazirino[3, 2-i] [2, 1] benzisothiazole, 8,8-dichlorotetrahydro-9,9-dimethy1-3,3-dioxide (365 g, 1.22 mol) in THF (1.1 L) dropwise over a period of 1.3 h at the same temperature. The reaction mass was allowed to come to -25 C in another 1.5h. After the complete
- 24 -conversion the system was quenched at -15 C with ice/water (2 L). Ethyl acetate (5 L) was added to the reaction mixture, the organic layer was separated and washed with water (3 L). The aqueous layer was saturated with NaCI and re-extracted with ethyl acetate (1 L). The combined organic layer was finally washed with brine, dried over Na2SO4 and concentrated to get the crude product which was purified by column chromatography (SiO2 230-400 mesh). The product eluted in 50-60% ethyl acetate and was obtained as off-white solid.
Amount obtained: 375 g; Yield: 73 A.
1H NMR (500 MHz, DMSO-de) ppm = 8.67 (t, J=6.4, 1H), 7.98 - 7.92 (m, 3H), 7.86 (d, J=2.2, 1H), 7.82 (d, J=3.7, 1H), 7.75 - 7.65 (m, 2H), 7.61 - 7.55 (m, 2H), 7.05 (tt, J=9.3, 2.4, 1H), 7.01 - 6.93 (m, 2H), 6.89 - 6.84 (m, 1H), 6.72 (s, 1H), 4.39 (dd, J=15.8, 6.8, 1H), 4.25 (dd, J=15.8, 6.0, 1H), 3.90 -3.83 (m, 2H), 2.65 - 2.54 (m, 1H), 2.17 - 2.09 (m, 1H). LCMS system A: H20+0,05%
HCOOH 1 system B: MeCN+0,04% HCOOH; T: 30 C 1 Flow:2,4m1/min 1 Column: Chromolith RP-18e 100-3 1 MS:85-800 amu. Gradient: 4% --> 100%
(B) 0--> 2,8 min 1100% (B) 2,8 - 3,3 min. retention time: 2.376 min (M+H+):
526.1.
Note: Average chiral purity achieved in this step was 85 % and the maximum is was 87 A. It is important that any washing of crude will result in a considerable reduction in the chiral purity.
Structure of Davis Oxaziridine:
ci ci 20 N, 0 0// s9j
Amount obtained: 375 g; Yield: 73 A.
1H NMR (500 MHz, DMSO-de) ppm = 8.67 (t, J=6.4, 1H), 7.98 - 7.92 (m, 3H), 7.86 (d, J=2.2, 1H), 7.82 (d, J=3.7, 1H), 7.75 - 7.65 (m, 2H), 7.61 - 7.55 (m, 2H), 7.05 (tt, J=9.3, 2.4, 1H), 7.01 - 6.93 (m, 2H), 6.89 - 6.84 (m, 1H), 6.72 (s, 1H), 4.39 (dd, J=15.8, 6.8, 1H), 4.25 (dd, J=15.8, 6.0, 1H), 3.90 -3.83 (m, 2H), 2.65 - 2.54 (m, 1H), 2.17 - 2.09 (m, 1H). LCMS system A: H20+0,05%
HCOOH 1 system B: MeCN+0,04% HCOOH; T: 30 C 1 Flow:2,4m1/min 1 Column: Chromolith RP-18e 100-3 1 MS:85-800 amu. Gradient: 4% --> 100%
(B) 0--> 2,8 min 1100% (B) 2,8 - 3,3 min. retention time: 2.376 min (M+H+):
526.1.
Note: Average chiral purity achieved in this step was 85 % and the maximum is was 87 A. It is important that any washing of crude will result in a considerable reduction in the chiral purity.
Structure of Davis Oxaziridine:
ci ci 20 N, 0 0// s9j
- 25 -Step C6: S-9 (S)-3-Hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylam ide H
HOE
2 Na0H/Et0H/THF
0, ,N HN
525.12 385.12 Experimental procedure:
Sodium hydroxide pellets (140 g, 3.56 mol) were added to a stirred suspension of 12 (375 g, 0.71 mol) in ethanol/THF mixture (3 L/1 L) at RT. The reaction mixture was heated at 50 C for 2 h. After the complete conversion the reaction mixture was concentrated to get the crude mass. Water (4 L) was added and stirred for 1 h at RT. The solid formed was filtered through a Buchner funnel, neutralized by washing with 1.5 N HC1followed by water (1 L
x 3). The residue was finally washed with ether (2 L) to get the crude product.
The chiral purity of the compound was checked at this stage and found to be 95.5 A. To increase the chiral purity the solid was dissolved in minimum amount of THF/ethyl acetate (9:1) and heated to reflux at 60 C for 30 min. The solution was filtered through a BOchner funnel and the clear filtrate was ice
HOE
2 Na0H/Et0H/THF
0, ,N HN
525.12 385.12 Experimental procedure:
Sodium hydroxide pellets (140 g, 3.56 mol) were added to a stirred suspension of 12 (375 g, 0.71 mol) in ethanol/THF mixture (3 L/1 L) at RT. The reaction mixture was heated at 50 C for 2 h. After the complete conversion the reaction mixture was concentrated to get the crude mass. Water (4 L) was added and stirred for 1 h at RT. The solid formed was filtered through a Buchner funnel, neutralized by washing with 1.5 N HC1followed by water (1 L
x 3). The residue was finally washed with ether (2 L) to get the crude product.
The chiral purity of the compound was checked at this stage and found to be 95.5 A. To increase the chiral purity the solid was dissolved in minimum amount of THF/ethyl acetate (9:1) and heated to reflux at 60 C for 30 min. The solution was filtered through a BOchner funnel and the clear filtrate was ice
- 26 -cooled for 2-3 h and the solid formed was filtered. The filtrate was ice cooled again for 2 h and the solid was separately filtered. Chiral purity of each solid was checked and all the fractions were mixed with ee >98.7% and finally purified by column chromatography (SiO2 230-400 mesh) using DCM/Me0H
as the eluent. The pure product was eluted with 2% methanol, concentrated under reduced pressure to get the desired S-9 as off white solid. The product was dried at 60 C for 12 h Amount obtained: 140 g; Yield: 51%.
Note 01: If the chiral purity of the crude S-9 was >97%, the mass was treated with minimum volume of ethyl acetate/THF (3V, 9:1), stirred for 30 min at RT
and filtered to give desired chiral purity >98.7%
Note 02: The main aqueous layer collected was acidified with 2N HCI and the solid formed was filtered. The cake was neutralized by washing with water and finally washed with cold ethyl acetate to give remaining compound with chiral purity of 60%.
as the eluent. The pure product was eluted with 2% methanol, concentrated under reduced pressure to get the desired S-9 as off white solid. The product was dried at 60 C for 12 h Amount obtained: 140 g; Yield: 51%.
Note 01: If the chiral purity of the crude S-9 was >97%, the mass was treated with minimum volume of ethyl acetate/THF (3V, 9:1), stirred for 30 min at RT
and filtered to give desired chiral purity >98.7%
Note 02: The main aqueous layer collected was acidified with 2N HCI and the solid formed was filtered. The cake was neutralized by washing with water and finally washed with cold ethyl acetate to give remaining compound with chiral purity of 60%.
Claims (9)
1. Process for manufacturing (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide ("S-9"), characterized in that a) 2-oxo-1-(1-(phenylsulfony1)-1H-indo1-5-yl)pyrrolidine-3-carboxylic acid ("5") is reacted with 3,5-difluorobenzyl amine to give 1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3, 5-difluorophenyl)methyl]-2-oxopyrrolidine-3-carboxam ide ("12"), b) "12" is then enantioselectively oxidized to give (35)-1-[1-(benzenesulfony1)-1H-indo1-5-y1]-N-[(3, 5-difluorophenyl)methy1]-3-hydroxy-2-oxopyrrolidine-3-carboxam ide ("13"), c) and subsequently the phenylsulfonyl group is cleaved off from "13" to give (S)-3-hydroxy-1-(1H-indo1-5-y1)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylam ide ("S-9").
2. Process according to claim 1, wherein a) is carried out in presence of a base selected from triethylamine, DBU or di-isopropylethylamine.
3. Process according to claim 1 or 2, wherein a) is carried out in dichloromethane.
4. Process according to claim 1, 2 or 3, wherein a) is carried out in the presence of propanephosphonic acid anhydride.
5. Process according to claim 1, wherein b) is carried out in presence of the oxidizing reagent (+)-(2R,4aS,75,8aR)-4H-4a, 7-methanooxazirino[3, 2-i] [2, 1] benzisothiazole, 8,8-dichlorotetrahydro-9,9-dimethy1-3,3-dioxide.
6. Process according to claim 1 or 5, wherein b) is carried out in presence of THF or diethylether.
7. Process according to claim 1, 5 or 6, wherein b) is carried out in presence of NaHMDS.
8. Process according to claim 1, wherein c) is carried out in presence of NaOH.
9. The intermediate compound 1 -[1 -(benzenesulfony1)-1 H-indo1-5-y1]-N-[(3, 5-difluorophenyl)methy1]-2-oxopyrrolidine-3-carboxamide (12).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19184056.0 | 2019-07-03 | ||
EP19184056 | 2019-07-03 | ||
PCT/EP2020/068317 WO2021001328A1 (en) | 2019-07-03 | 2020-06-30 | Process for manufacturing (s)-3-hydroxy-1-(1h-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3145579A1 true CA3145579A1 (en) | 2021-01-07 |
Family
ID=67145670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3145579A Pending CA3145579A1 (en) | 2019-07-03 | 2020-06-30 | Process for manufacturing (s)-3-hydroxy-1-(1h-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220251072A1 (en) |
EP (1) | EP3994134B1 (en) |
JP (1) | JP2022538364A (en) |
KR (1) | KR20220028030A (en) |
CN (1) | CN114026069A (en) |
AU (1) | AU2020299711A1 (en) |
BR (1) | BR112021026624A2 (en) |
CA (1) | CA3145579A1 (en) |
DK (1) | DK3994134T3 (en) |
FI (1) | FI3994134T3 (en) |
IL (1) | IL289479A (en) |
MX (1) | MX2021016001A (en) |
PT (1) | PT3994134T (en) |
TW (1) | TW202116756A (en) |
WO (1) | WO2021001328A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010048374A1 (en) | 2010-10-13 | 2012-04-19 | Merck Patent Gmbh | Pyrrolidinones as MetAP-2 inhibitors |
DE102012006884A1 (en) | 2012-04-04 | 2013-10-10 | Merck Patent Gmbh | Cyclic amides as MetAP-2 inhibitors |
PL3177603T3 (en) * | 2014-08-04 | 2019-03-29 | Merck Patent Gmbh | Pyrrolidinone derivatives as metap-2 inhibitors |
AU2016219362B2 (en) * | 2015-02-11 | 2019-11-14 | Theravance Biopharma R&D Ip, Llc | (2S,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor |
EP3259255B1 (en) * | 2015-02-19 | 2020-10-21 | Theravance Biopharma R&D IP, LLC | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
-
2020
- 2020-06-30 FI FIEP20734955.6T patent/FI3994134T3/en active
- 2020-06-30 PT PT207349556T patent/PT3994134T/en unknown
- 2020-06-30 KR KR1020227003063A patent/KR20220028030A/en unknown
- 2020-06-30 JP JP2022500028A patent/JP2022538364A/en active Pending
- 2020-06-30 EP EP20734955.6A patent/EP3994134B1/en active Active
- 2020-06-30 BR BR112021026624A patent/BR112021026624A2/en unknown
- 2020-06-30 AU AU2020299711A patent/AU2020299711A1/en active Pending
- 2020-06-30 CA CA3145579A patent/CA3145579A1/en active Pending
- 2020-06-30 DK DK20734955.6T patent/DK3994134T3/en active
- 2020-06-30 MX MX2021016001A patent/MX2021016001A/en unknown
- 2020-06-30 CN CN202080048299.1A patent/CN114026069A/en active Pending
- 2020-06-30 US US17/597,102 patent/US20220251072A1/en active Pending
- 2020-06-30 WO PCT/EP2020/068317 patent/WO2021001328A1/en unknown
- 2020-07-02 TW TW109122384A patent/TW202116756A/en unknown
-
2021
- 2021-12-29 IL IL289479A patent/IL289479A/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK3994134T3 (en) | 2024-04-15 |
JP2022538364A (en) | 2022-09-01 |
EP3994134B1 (en) | 2024-01-24 |
MX2021016001A (en) | 2022-01-24 |
TW202116756A (en) | 2021-05-01 |
FI3994134T3 (en) | 2024-04-24 |
BR112021026624A2 (en) | 2022-05-10 |
AU2020299711A1 (en) | 2022-02-24 |
EP3994134A1 (en) | 2022-05-11 |
KR20220028030A (en) | 2022-03-08 |
PT3994134T (en) | 2024-04-23 |
IL289479A (en) | 2022-02-01 |
WO2021001328A1 (en) | 2021-01-07 |
US20220251072A1 (en) | 2022-08-11 |
CN114026069A (en) | 2022-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CZ245093A3 (en) | Novel thiopyranopyrrole derivatives and process of their preparation | |
CA3115587A1 (en) | Process for the preparation of a pde4 inhibitor | |
JP2023116769A (en) | Method for producing edoxaban | |
ITMI951688A1 (en) | BICYCLIC LACTAM DERIVATIVES AS THROMBIN INHIBITORS | |
CN1821217B (en) | Process for producing trans-4-amino-1-cyclohexanecarboxylic acid derivative | |
ES2245690T3 (en) | PROCEDURE TO PREPARE ARILACETILAMINOTIAZOLES. | |
CA3145579A1 (en) | Process for manufacturing (s)-3-hydroxy-1-(1h-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide | |
CZ72095A3 (en) | Benzenealkanoic acids as such and for use in medicine, process of their preparation and their use for the preparation of medicaments and pharmaceutical preparations based thereon | |
RU2813291C2 (en) | Method of producing 3,5-difluorobenzylamide (s)-3-hydroxy-1-(1h-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid | |
US10752585B2 (en) | Process for the preparation of Zafirlukast and analogs thereof | |
KR100373375B1 (en) | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME(ICE OR CASPASE 1) AND APOPAIN/CPP-32(CASPASE-3) | |
CN109280055A (en) | The method of asymmetric synthesis of ergot alkaloid | |
CN109641863B (en) | Intermediate for synthesizing carfilzomib and synthesis of pharmaceutically acceptable salt thereof | |
CN102333763A (en) | 1, 5-benzene diazide derivs | |
RU2698202C2 (en) | METHOD FOR PRODUCING DIRECT FACTOR Xa INHIBITOR | |
US6258956B1 (en) | Synthesis of 3-amino-3-aryl propanoates | |
WO2000055145A1 (en) | 1,3,4-oxadiazole derivatives and process for producing the same | |
JP4153644B2 (en) | Method for producing 2-alkyl-3-aminothiophene derivative and 3-aminothiophene derivative | |
JP7257115B2 (en) | Novel sulfonamide intermediate and method for producing silodosin using the same | |
WO2010061621A1 (en) | Method for manufacturing trans-{4-[(alkyl amino) methyl] cyclohexyl} acetic ester | |
US6388083B2 (en) | Process for the synthesis of (2S)-phenyl-3-piperidone | |
KR101032761B1 (en) | A method for preparing docetaxel and new intermediates for preparing the same | |
EP1698611A1 (en) | Process for producing phenylacetic acid derivative | |
JP2020533365A (en) | New compounds useful in the manufacture of pharmaceuticals | |
JPH05221947A (en) | Production of cyclopropane derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20240315 |